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Abstract: Idiopathic short stature (ISS) is a term that describes short stature in children who 
do not have growth hormone (GH) deficiency and in whom the etiology of the short stature 
is not identified. Between 1985 and 2000, more than 40 studies were published regarding GH 
therapy for ISS. Only 12 of these had data to adult height, of which only 4 were controlled 
studies. A subsequent placebo-controlled study that followed subjects to adult height indicated 
that there was a gain of 3.7–7.5 cm in height with GH treatment. In 2003, the US Federal Drug 
Administration (FDA) approved GH for treatment of short stature. Even before FDA approval, 
patients with ISS made up about 20% of patients in GH databases, which is largely unchanged 
since FDA approval. There remains some controversy as to whether GH should be used to treat 
ISS. This controversy centers on the fact that there has been no definitive demonstration that 
short stature results in a disadvantage or problems with psychological adjustment, and thus, no 
demonstration that GH therapy results in improvement in quality of life.
Keywords: idiopathic short stature, ISS, growth hormone therapy, somatotropin, somatropin, 
insulin-like growth factor I, IGF-1
Introduction
Idiopathic short stature (ISS) is one of several terms that have been used to describe short 
stature in children who do not have growth hormone (GH) deficiency and in whom the 
etiology of their condition is not understood. Other terms that have been used in the past 
to describe these children, some overlapping those that describe ISS, include familial 
short stature, normal variant short stature, idiopathic growth failure, non-GH-deficient 
short stature, and nonendocrine short stature. Some patients with ISS have been diagnosed 
with GH neurosecretory dysfunction (ie, low spontaneous GH secretion) as a means of 
justifying GH therapy. All recognizable causes of short stature (ie, intrauterine growth 
retardation, genetic or syndromic causes of short stature, and psychosocial deprivation) 
should be ruled out before a diagnosis of ISS is made.1 As a group, children with ISS 
do not achieve their adult height predictions, and many have adult heights that are quite 
short.2,3 As more is understood about the causes of short stature, it is hoped that many of 
these children may eventually have a more definitive diagnosis. An example of this situ-
ation is a recent report of a child with ISS who was ultimately diagnosed with a   deletion 
in exon 5 of the Short Homeobox X (SHOX) gene.4
A short history of GH therapy
The first report on GH therapy for growth hormone deficiency (GHD) was produced 
in 1958.5 The first GH preparations (somatotropin) used therapeutically were derived  Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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from human cadaver pituitaries. In the United States, human-
derived growth hormone was produced and distributed by 
the National Institute of Health’s (NIH) National Pituitary 
Agency. The preparation was in short supply, resulting in 
lower than ideal dosing and frequent drug holidays. Potential 
recipients were required to participate in a research protocol 
and, in order to ration the cadaveric GH, the diagnosis of 
GH-deficiency required that the patient have a peak GH level 
in response to provocative stimuli below a certain level. This 
requirement gradually increased in response to a better sup-
ply of cadaveric GH, starting at 5 ng/mL, then 7 ng/mL, and 
finally 10 ng/mL in the early 1980s. In 1985, this preparation 
was linked to a risk for Creuzfeldt-Jacob disease,6,7 and its 
use was discontinued. In 1979, GH was produced in large 
quantities by expressing the human GH gene in Escherichia 
coli.8 In 1985, Genentech Inc. (San Francisco, CA, USA) 
was approved by the Food and Drug Administration (FDA) to 
market recombinant human growth hormone (rhGH),9 which 
was identical to human growth hormone, with the addition 
of a methionine as a necessary start signal for the bacteria 
to initiate protein synthesis. Use of methionyl GH did result 
in antibody production, but this was rarely associated with 
growth attenuation.10 Present-day commercial preparations 
(somatropin) all have the identical 191-amino acid sequence 
of native human pituitary hormone.11
Initially, GH was injected intramuscularly. But, in the 
mid-1980s (about the time of introduction of rhGH), it 
was shown to be as effective if given as a subcutaneous 
injection,12 which is the practice today. Early in its use, GH 
was given twice weekly, but this was increased to three times 
weekly when the higher frequency was shown to result in 
an increased growth response.13 At about the time of the 
transition from cadaveric GH to rhGH, it was demonstrated 
that daily injections (6 or 7 per week) yielded an even better 
growth response than the three times per week schedule,14–17 
and daily administration is commonly used today.
GH treatment of ISS
During the time of cadaveric growth hormone, usage was 
limited to GHD because of the scarcity of supply. However, 
even before the advent of rhGH, there was interest in investi-
gating whether treatment of other conditions associated with 
short stature would increase adult stature. Between 1964 and 
1971, there were a number of small studies that examined 
the treatment of non-GH-deficient short stature with GH.18 
In 1964, the National Institute of Child Health and Human 
Development (NICHD), a branch of the NIH, sponsored 
an international conference that recommended analysis of 
GH treatment in non-GH-deficient conditions. In 1983, 
a   conference s  ponsored by the NICHD, entitled   International 
Conference on Uses and Abuses of Growth Hormone, brought 
up this topic, resulting in the following statement: “… there is 
an urgent need for therapeutic trials to determine the effect of 
growth hormone in short children who do not have a growth 
hormone deficiency”. In 1987, a FDA committee recom-
mended a placebo-controlled study of GH treatment for ISS 
that would follow subjects to adult height.
A placebo-controlled trial of treatment of children with 
ISS in collaboration with Eli Lilly (Indianapolis, IN, USA) 
and the NIH was carried out between 1988 and 2001. Data 
from this trial were presented to the NIH. In July 2003, the 
FDA approved the use of GH in children with ISS. They 
defined children with ISS as those having a height that was 
greater than 2.25 standard deviations (SD) below the mean 
(one of the inclusion criteria of the Eli Lilly/NIH collabora-
tive trial), open epiphyses, a growth velocity that makes it 
unlikely that the child’s adult height will be in the normal 
range (ie, within 2 SD of the mean), and a diagnostic evalu-
ation that has excluded other causes associated with short 
stature, which would better be managed by observation or 
treatment by other means. One of the concerns has been the 
possibility of misdiagnosing and treating children for ISS 
who actually have constitutional delay in growth and matu-
ration (CD), particularly if the child’s bone age is delayed. 
Certainly, there are such patients. However, if the FDA 
guidelines are adhered to, a child who is more than 2.25 SD 
below the mean, and has a predicted adult height that is more 
than 2 SD below the mean, is probably more appropriately 
considered to have ISS than to be classified as having CD. 
There is evidence that adult height tends to be overpredicted, 
particularly in boys.19
According to a recent survey of pediatric endocrinologists, 
there is still not agreement as to whether or when children with 
ISS should be treated.20 Most of the respondents to the survey 
agreed that there was a need for indication. Respondents were 
asked about the cut-off height of -2.25 SD. 71% responded 
that it was appropriate, 21% thought it should be  set higher, 
and 8% thought it should be set lower. When asked about 
factors contributing to willingness to prescribe (78% selected 
more than one response), 53% selected “patient expression 
of understanding potential risk and benefits”, 32% selected 
“family insistence”, 14% selected “family’s desire to pay”, and 
7% selected “male gender”. The case against treatment is that 
there is not a convincing body of evidence to indicate that short 
stature is actually a real problem, or that treatment (or taller 
stature) leads to any psychological benefit.21   Treatment of Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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GHD is justified because it represents replacement of a miss-
ing hormone. On the side of treating ISS patients, Saenger22 
argues that the diagnosis of GHD is very difficult to make 
with certainty, and in the absence of meaning psychological 
outcome data, we should follow the recommendation of the 
American Academy of Pediatrics,23 which recommends treat-
ment of very short children whose ability to participate in 
basic activities of daily living is limited because of their short 
stature. One of the fears after ISS became an FDA-approved 
indication was that there would be a change in the paradigm 
determining which short children are treated (resulting in 
the treatment of many more children who were not as short). 
We compared demographic data in the National Cooperative 
Growth Study (NCGS) of children who were treated for ISS 
before 2003 and from 2003–2006 (ie, after FDA approval).24 
Although no major changes were seen, there was a very small 
decrease in the severity of the growth retardation at entry, 
and a slight increase in the treatment doses. Mean height 
velocities during treatment were the same before and after 
FDA approval.
Efficacy of GH treatment in ISS
Children with ISS who are treated with GH are as short at 
the beginning of GH therapy as children with chronic renal 
insufficiency, Turner syndrome, or those who are born small 
for gestational age: that is, their heights before treatment aver-
age from -2.6 SD to -2.9 SD.25–29 In this group of children, 
insulin-like growth factor-1 (IGF-1) levels are often normal. 
However, approximately 25% of them are low, suggesting 
that some children in this group may have GH-insensitivity. 
Many of the published studies of GH therapy in children 
with ISS have involved small sample sizes and did not have 
control groups (28 uncontrolled vs 10 with a control group).18 
Even with these limitations, a meta-analysis of these studies 
suggested that the overall height gain may have been from 
-3.0 to -1.5 SD with GH therapy,18 which represents a 
height increase of 4–6 cm. In studies with a control group, it 
appeared that the control group also had an increase in height 
(consistent with a previous report of spontaneous growth 
in children with ISS),30 but the treated group exceeded the 
control group by approximately 0.78 SD. Subsequent to this 
meta-analysis, results of a placebo-controlled study on the 
effect of GH therapy on adult height in peripubertal children 
with ISS demonstrated a height increase of 3.7–5.0 cm with 
GH therapy, despite a low dose of GH (0.22 mg/kg/week) 
and an injection schedule of three times per week.31 A   second 
study evaluating two treatment protocols demonstrated a 
dose effect with a dosage of 0.37 mg/kg/week resulting in 
an increase in adult height of 7.2 cm compared with 5.4 cm 
in the group receiving only 0.24 mg/kg/week.32 A recent 
report of comparison of two doses (0.23 and 0.47 mg/kg/
week) of GH and an untreated population in a group of 
177 children, most of whom had ISS, showed that there was 
a dose-dependent increase in adult height,33 with a gain of 
about 1.5 SD in the group treated with the higher dose. An 
evaluation of data from children with ISS treated with GH, 
taken from a large GH database, showed that GH treatment 
resulted in an increase in height from -3.0 to -1.2 SD over 
the course of 7 years.26 Factors that tend to predict a posi-
tive response to GH treatment include GH dose, degree of 
height deficit compared to parents’ heights, young age, and 
first year height velocity.1,34
Safety of GH treatment in ISS
An evaluation by Quigley et al35 of safety data from the 
controlled trial of GH therapy of children with ISS31 and the 
subsequent dose-response study,32 as well as an evaluation 
of more than 8,000 ISS patients followed in a large post-
marketing database for children treated with GH,26 have 
shown that there are no safety issues in GH therapy different 
from those seen with treatment of GH deficiency.
Psychosocial effect of treating ISS
It is assumed that short stature is associated with disadvan-
tages and problems of psychological adjustment. Anecdotal 
reports include teasing, treating children in relation to their 
height rather than their age (juvenilization), and academic 
underachievement.36 Some studies seem to confirm these 
notions,37–40 while others have failed to demonstrate any 
disadvantage to short stature, including any problem with 
psychological adjustment.41–44 In fact, Kranzler et al45 
evaluated 90 children who were sent to a stature clinic, and 
determined that they had normal psychological function 
without externalizing behavior problems, attention problems, 
or poor social skills, as had been previous reported.39,46,47 
Sandberg48 reported that juvenilization does occur, but short 
stature is not associated with any social advantage. Balen 
et al49 have suggested that patients referred for ISS seem to 
be more at risk for psychological problems than those who 
are not referred. Further, they indicate that, in addition to 
stature, there are other risk factors for psychological diffi-
culty, including being juvenilized, being a boy, having low 
intelligence, having a younger but taller sibling, and being 
part of a family with low socioeconomic status. In light of 
this controversy, it is not surprising that it has been diffi-
cult to demonstrate that treatment of ISS (and short stature  Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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in general) improves the quality of life of the individual. 
Many who treat children with ISS believe that by increasing 
adult height they are improving quality of life.50 However, 
there is little objective data to support this notion.51 In fact, 
the idea that short stature is a problem that can be addressed 
by GH treatment has been recently challenged in the popular 
press.52 Recent reviews of available instruments for evalu-
ating quality of life in children with GHD or ISS suggest 
that it should be possible to do the studies that could help 
answer whether treatment with GH has a positive or negative 
effect on quality of life.53,54 The question of efficacy of GH 
treatment is particularly relevant because of the expense of 
GH therapy: perhaps as much as US$52,634 per inch.55 In 
spite of the difficulty of demonstrating that an increase in 
height also results in increased quality of life, children with 
ISS have been treated with GH since at least the inception 
of the NCGS in 1985, accounting for approximately 20% 
of those patients treated with GH.56 Savage57 has suggested 
that 1) if growth hormone therapy is restricted to a height 
threshold of -2.5 or -3.0 SD, and 2) if treatment would be 
limited to those children with slow height velocity, there 
might be fewer children who would experience a benefit in 
terms of taller stature than would have been attained without 
treatment. Further, Savage indicates that continued treatment 
should depend upon an increase in height velocity of at least 
2 cm/year; if such an increase in height velocity does not 
occur, GH therapy should be discontinued.
Evidence that some ISS cases may 
be caused by genetic mutations  
in GH-IGF-1 axis
The GH receptor gene is the first gene that was associated 
with growth failure, possibly including ISS. It is well rec-
ognized that mutations in the GH receptor are responsible 
for complete GH-resistance (also known as GH-insensitivity 
syndrome), in which it has been possible to identify about 
70%–80% of patients with low levels of GH binding pro-
tein (GHBP), which is the extracellular portion of the GH 
receptor. About 30 distinct mutations have been described.58 
Point mutations of the intracellular domain have also been 
described. However, most of these have also been found 
in subjects with normal height, and have been considered 
to be polymorphisms.59–61 In order to determine whether 
partial GH-insensitivity was responsible for growth failure 
in children with ISS, data were analyzed from 773 children 
who were being treated with GH and were enrolled in a post-
marketing surveillance project, the NCGS.62 Patients enrolled 
in this study had their levels of insuline-like growth factor 1 
(IGF-1) and GHBP determined. In addition, these patients 
had been evaluated for GH-deficiency by their response to 
provocative stimuli. Patients with a GH response of more than 
10 ng/mL were classified as having ISS. Children with ISS 
had GHBP levels more than 2 SD below the normal control 
patients, IGF-1 levels lower than controls (108–120 µg/L 
vs 217–308 µg/L), but higher than in patients with GH-
deficiency (84–99 µg/L), and mean 12 hour GH concentra-
tions similar to controls (2.2 µg/L vs 2.1–2.7 µg/L), but 
higher than in patients with GH-deficiency (1.2–1.4 µg/L). 
A subset of 14 of these patients (height more than 2.5 SD 
below mean, normal GH secretion, IGF-1 levels more than 
2 SD below the mean, and serum concentrations of GHBP 
more than 2 SD below the mean) were further studied.63 
Of the 14 patients, four had mutations in the GH receptor 
(none of the 24 control subjects had mutations). One of these 
patients was a compound heterozygote with respect to the 
GH receptor. Due to these findings, it has been suggested that 
partial GH-insensitivity may be a cause of growth failure in 
some children with ISS. It may be possible that they would 
respond to GH at higher doses, or it may be that these children 
should be treated with IGF-1 instead of GH. Certainly, the 
case can be made that mutations in the GH receptor could 
explain ISS in some of the patients. In a recent study, a pool 
of 188 patients with ISS were analyzed for mutations in the 
GH receptor in order to determine if finding these mutations 
would predict response to therapy. Mutations were present in 
fewer than 5% of the patients, and discovery of single-gene 
defects did not predict treatment response.64
A second area of inquiry has been the SHOX gene. This 
gene resides on the distal ends of the short arms of chromo-
somes X and Y (in the pseudoautosomal region).65 It appears 
that two functional copies of this gene are required for attain-
ment of normal stature. Thus, absence of this gene from the 
loss of one or part of one X chromosome is associated with 
the short stature of Turner syndrome. Likewise, a mutation 
in one of the SHOX genes has been shown to be the cause of 
Leri-Weill syndrome, also known as dyschondrosteosis.66,67 
Screening of ISS patients for abnormalities in the SHOX 
gene has been a logical step. Rao65 reported one patient with 
a functionally significant mutation in the SHOX gene out of 
91 patients with ISS screened. Ogata68 expanded the screen to 
include 400 patients with ISS, and found the aforementioned 
patient, along with 3 others with SHOX gene mutations. In 
an analysis of 68 patients with ISS, one female patient was 
identified who had a normal karyotype but a deletion of one 
SHOX allele.69Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Other gene defects that have recently been discovered to 
result in growth failure include defects in the growth hor-
mone receptor’s intracellular signaling, in particular, signal 
transducer and activator of transcription 5b (STAT5b),70 and 
a defect in the acid-labile subunit (ALS) of the circulating 
IGF-1 complex.71 STAT5b-deficiency results in a phenotype 
of GH-insensitivity and immunodeficiency, while ALS-
deficient patients have rather subtle growth failure, with 
height tracking at about or just below the 3rd centile. Neither 
of these defects has been identified in patients diagnosed as 
having ISS,64,72 perhaps in part because they represent very 
rare disorders. Also, it has been pointed out that the phenotype 
of STAT5b-deficiency is that of severe GH-resistance, and it 
is not likely to be mistaken for ISS.64 Perhaps the reason that 
ALS-deficiency has not been identified in a population of ISS 
patients is because the growth failure associated with it is too 
subtle for the affected child to be labeled as having ISS.
It appears that mutations in the GH receptor and the 
SHOX gene account for between 1% and 5% of the cases 
of growth failure that are designated ISS. As more patients 
with ISS are investigated, it is likely that additional genes 
responsible for growth failure will be discovered. As we 
recognize various causes for ISS, the pool of children with 
this designation should continue to decrease.
IGF-1 treatment of ISS
In August and December of 2005, mecasermin IGF-1 
(Increlex®, Tercica Inc, Brisbane, CA, USA) and mecaser-
min rinfabate IGFBP-3 (Insulin-like growth factor binding 
protein 3) (Iplex®, Insmed, Glen Allen, VA, USA) received 
approval from the FDA for the treatment of children with 
severe primary IGF-deficiency or children with a GH gene 
deletion who have developed neutralizing antibodies to GH. 
Mecasermin rinfabate is no longer available for treating con-
ditions with short stature because of a legal agreement. These 
compounds have been shown to be effective in treating cases 
of GH-insensitivity73,74 and IGF gene deletion.75 In spite of ISS 
being an off-label use, there was a poster presentation of data 
from the Increlex Growth Forum Database Registry at the 2007 
meeting of the Endocrine Society,76 which showed that 17% of 
enrolled patients were identified as having ISS. Rosenbloom77 
has  assented that “partial GH-insensitivity” is not evidence-
based, but represents an attempt by the manufacturer to promote 
use of their product by a wider market than the rather small 
number of patients with true GH-insensitivity.77 Because of 
the paucity of published data regarding the treatment of ISS 
(or partial GH-insensitivity), the role of treatment of ISS with 
IGF-1 remains to be determined.78,79
Treatment of GH receptor-deficiency with IGF-1 has 
resulted in a number of mild to moderate adverse events. 
Most commonly reported adverse events have included 
pain at the injection site and headaches. Data from a 
  European study indicate that these events occur during the 
first month of treatment and then improve.80 Other adverse 
events that have been reported following IGF-1 therapy 
have included lipohypertrophy at the injection site, papil-
loedema related to increased intracranial hypertension, and 
facial nerve paralysis.81,82 With these events, symptoms 
resolved after interrupting treatment and re-starting with a 
lower dose.80,83
A second concern has been hypoglycemia, which 
occurred in some of the patients receiving IGF-1, but only 
rarely resulted in seizures.73,84 This problem was lessened by 
administering the IGF-1 dose with meals, and hypoglycemia 
was usually a problem when there was an intercurrent illness 
resulting in loss of appetite.
Another effect of IGF-1 therapy has been the growth 
of lymphoid tissue, in particular, splenic enlargement and 
tonsillar hypertrophy. Renal size also increased, but renal 
function remained normal.73 There were changes in facial 
appearance, with coarsening of features and an increase in 
hair growth, which were most noticeable during puberty. 
A complex of IGF-1 and IGFBP-3 appears to prolong 
the half-life and might counteract acute adverse events, 
particularly hypoglycemia associated with administration 
of IGF-1.
A recent report of treatment of 136 short children (pre-
sumable ISS) with IGF-185 showed that there was a statisti-
cally significantly increased growth velocity in the groups 
receiving 80 or 120 µg/kg twice daily vs a non-treated control 
group. However, there were significant reports of adverse 
events in the group: headaches 38%, vomiting 25%, and 
hypoglycemia 14%; in fact, six subjects withdrew because of 
adverse events. In an accompanying editorial, Rosenbloom 
and Rivkees86 question whether there is adequate growth 
promotion to justify the apparent risks of treating with IGF-1 
in this population.
Other approaches to treatment  
of ISS
LHRH agonists
It is well-recognized that treatment of early-onset preco-
cious puberty with luteinizing hormone-releasing hormone 
(LHRH) agonists such as gonadotropin-releasing hormone 
agonist (GnRHa) allows adult height to approach target 
height.87 It has been postulated that GH may hasten the  Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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  progression of puberty, and that the addition of GnRHa 
treatment may permit further growth in children with ISS. 
Kamp et al demonstrated that the addition of GnRHa to GH 
therapy in children with ISS or intrauterine growth restriction 
resulted in an increase in predicted adult height of 8.0 cm in 
girls and 10.4 cm in boys.88 A prospective study comparing 
treatment of normal short girls with GH alone or with GH 
plus GnRHa suggested that while GH alone resulted in an 
increase in predicted adult height, the addition of GnRHa 
combined with GH resulted in an even greater increase in 
predicted adult height.89 The evaluation of two large GH 
registry databases,90 GH prediction models,90 and a recent 
report of lack of efficancy in increasing adult height when 
treatment is initiated after the age of 7–8 years91 do not sup-
port the success of this treatment. At present, there are no 
universally agreed upon guidelines for the use of GnRHa with 
(or without) GH in children with ISS. Thus, this therapy is 
still considered experimental.
Aromatase inhibitors
A recent study has demonstrated a 5.9 cm increase in pre-
dicted adult height in boys with ISS using an inhibitor of 
aromatase (letrozole) without GH treatment for 24 months.92 
The same group has reported a similar finding in boys 
with constitutional delay treated to near adult height with 
letrozole.93 The group receiving letrozole reached a near 
adult height which was 6.7 cm taller than those who did 
not. Although these reports appear quite promising, further 
studies carried out to adult height, with a careful evaluation 
of safety, are needed before this therapy can be adopted in 
a clinical setting.87
Conclusion
ISS describes a group of children who are very short (more 
than 2 SD below the mean) and who are not GH-deficient. 
As early as 1983, there was interest in determining whether 
treating these children increased their adult height. Between 
1985 and 2000, there were more than 40 studies published 
on the treatment of ISS. Most involved small patient popu-
lations, only 12 had adult height data, and only four were 
controlled. A controlled study was undertaken between the 
NHI and Eli Lilly. Subsequently, that study demonstrated an 
increase in adult height from 3.7–7.5 cm (1.5–3 inches) with 
GH treatment.31,32 The FDA approved the ISS indication in 
July 2003. An analysis of the data from a large registry of 
patients receiving GH demonstrated a similar response to 
therapy and no differences in safety than for the treatment of 
GH-deficiency. Genetic explanations for ISS have occurred 
in approximately 5% of the patients evaluated, including 
genetic mutations of the GH-IGF-1 axis, including STAT5b 
mutations, SHOX gene mutations, and ALS mutations. With 
time, there will likely be a larger group of patients in which 
the etiology of their short stature is   elucidated. There are few 
data regarding whether a psychological advantage is gained 
by patients with ISS treated with GH. Other approaches 
to treating ISS include treating with IGF-1 (alone or in 
combination with GH), which has the added risk of adverse 
events, or delaying puberty with LHRH agonists or aro-
matase inhibitor. Both of the latter approaches are still in 
experimental stages.
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